Update of diagnostic and prognostic markers in cutaneous malignant melanoma

Clinics in Laboratory Medicine

Volumn 20, Issue 4, 2000, Pages 817-838

  Reed, J A ^a   Albino, A P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CD40 ANTIGEN; CELL ADHESION MOLECULE; FAS ANTIGEN; HERMES ANTIGEN; INTEGRIN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; MYC PROTEIN; PLASMINOGEN ACTIVATOR; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VASCULOTROPIN;

APOPTOSIS; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; DISEASE COURSE; DISEASE MARKER; HUMAN; MELANOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

FEMALE; HUMANS; MALE; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034484678     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. The p53 network
2. The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma
3. Molecular biology of cutaneous malignant melanoma
4. Mutation and expression of the p53 gene in human malignant melanoma
5. The unokinase-type plasminogen activator system in cancer metastasis: A review
6. Cutaneous melanoma
7. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and enhanced cellular invasion by melanoma cells
8. Cutaneous melanoma
9. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma
10. C-myc is not useful as a prognostic immunohistochemical marker in cutaneous melanoma
11. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma
12. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
13. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin
14. Correlation between lipid-associated sialic acid and tumor burden in melanoma
15. BCL-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi
16. Changing views of the role of matrix metalloproteinases in metastasis
17. Bcl-2 family: Regulators of cell death
18. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
19. Transforming growth factor-beta (TGF-β)
20. Model predicting survival in stage I melanoma based on tumor progression
21. Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma
22. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts
23. Heterogenous expression of immunotherapy candidate proteins gp 100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
24. The plasminogen activation system in melanoma cell lines and in melanocytic lesions
25. High CD44 surface expression on primary tumors of malignant melanoma correlates with increased metastatic risk and reduced survival
26. Cell proliferation-associated nuclear antigen defined by antibody Ki-67: A new kind of cell cycle-maintaining proteins
27. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1
28. Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation
29. Etiology, epidemiology, risk factors, and public health issues of melanoma
30. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of endothelial growth factor expression and angiogenesis
31. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
32. Clinical applications of research on angiogenesis
33. p21-negative regulator of the cell cycle
34. p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors
35. Up-regulated expression of the beta3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors in nude mice
36. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas
37. CD40 and CD154 in cell-mediated immunity
38. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma
39. Bcl-2 expression in malignant melanoma and its prognostic significance
40. Melanoma cell expression of FAS (Apo-1/CD95) Ligand: Implications for tumor immune escape
41. Prognostic value of serum analyses of s-100 protein beta in malignant melanoma
42. CD44 expression in melanocytic lesions: A marker of malignant progression?
43. Beta3 integrin expression in melanoma predicts subsequent metastasis
44. The alpha v beta 3 integrin "vitronectin receptor"
45. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells
46. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas
47. Mitotic rate and S-phase fraction as prognostic factors in stage 1 cutaneous malignant melanoma
48. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
49. Evidence for large upward trends of ultraviolet B radiation linked to ozone depletion
50. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions
51. Differential expression of growth arrest, DNA damage genes and tumor suppressor gene p53 in naevi and malignant melanomas
52. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma
53. Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma
54. CD44 expression in benign and malignant nevomelanocytic lesions
55. Role of the p16 tumor suppressor gene in cancer
56. Effects of clouds and stratospheric ozone depletion on ultraviolet radiation trends
57. Expression of CD44 splice variants in human cutaneous melanoma and melanoma call lines is related to tumor progression and metastatic potential
58. Analysis of expression of the melanoma-associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in situ lesions
59. Nevoid malignant melanoma: Morphologic patterns and immurtohistochemical reactivity
60. Evaluation of new putative tumor markers for melanoma
61. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line
62. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis
63. Clinical significance of alpha(v) beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions
64. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor
65. Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene
66. Cell proliferation markers in predicting metastases in malignant melanoma
67. Human cutaneous mast cells express basic fibroblast growth factor
68. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization: Implications for tumor progression
69. Expression of the mast cell growth factor interleukin 3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: Implications for melanoma progression
70. Expression of transforming growth factor-b2 in malignant melanoma correlates with the depth of tumor invasion: Implications for tumor progression
71. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
72. Recent developments in the cell biology of basic fibroblast growth factor
73. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
74. Mast cells and tumour angiogenesis: The tumour-mediated release of an endothelial growth factor from mast cells
75. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4.00mm thick) cutaneous melanoma. A quantitative assay
76. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma
77. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi
78. Predicting ten-year survival of patients with primary cutaneous melanoma: Corroboration of a prognostic model
79. Enhanced expression of vascular endothelial growth factor in metastatic melanoma
80. Circulating adhesion molecules as prognostic factors for cutaneous melanoma
81. In situ analysis of transforming growth factor-betas (TGF-beta1, TGF-beta2, TGF-beta3), and TGF-beta type II receptor expression in malignant melanoma
82. A prognostic model for predicting 10-year survival in patients with primary melanoma. The pigmented lesion group
83. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma
84. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential
85. Isolation and functional characterization of the A32 melanoma-associated antigen
86. Melanoma cell-cell interactions are mediated through heterophilic Meb-CAM/ligand adhesion
87. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials
88. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications
89. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma
90. CD44 as a marker in human cancers
91. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma
92. Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma
93. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value
94. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
95. Melanoma-associated expression of transforming growth factor-beta isoforms
96. CD40 is a prognostic marker in primary cutaneous malignant melanoma
97. Bcl-2 expression in human melanocytes and melanocytic tumors
98. Properties of metastasizing and nonmetastasizing human melanoma cells
99. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma
100. Mutations and defective expression of the WAF1 p21 tumor-suppressor gene in malignant melanomas
101. Vascularity and prognosis of metastatic melanoma
102. p53 protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin
103. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
104. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain
105. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
106. Collagenase immunolocalization studies of cutaneous secondary melanomas
107. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis
108. Expression of the p53 protein in malignant melanomas as a prognostic indicator